FDA Approves Verquvo (vericiguat) for Heart Failure with Reduced Ejection Fraction

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Verquvo, a soluble guanylate cyclase (sGC) stimulator, to reduce...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news